The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Nanocrystal technology, drug delivery and clinical applications
Open accessAbstract
Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE RATE OF SOLUTION OF SOLID SUBSTANCES IN THEIR OWN SOLUTIONS.
Noyes, A. A., & Whitney, W. R. (1897) · Journal of the American Chemical Society · doi:10.1021/ja02086a003 · Cited by 1,884
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Self-citationWhat is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Nanosizing: a formulation approach for poorly-water-soluble compounds
Merisko-Liversidge, E., Liversidge, G. G., & Cooper, E. R. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00251-8 · Cited by 1,263
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Ivanov, A. A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 539
Nanosuspensions for the Formulation of Poorly Soluble Drugs
Müller, R., Jacobs, C., & Kayser, O. (2000) · Drugs and the Pharmaceutical Sciences · doi:10.1201/b14005-13 · Cited by 501
Self-citationLiversidge, G. G., & Conzentino, P. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)00148-c · Cited by 294
Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., et al. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.08.001 · Cited by 275
Willems, L., van der Geest, R., & de Beule, K. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00338.x · Cited by 227
Nanostructured hybrid materials from aqueous polymer dispersions
Castelvetro, V., & De Vita, C. (2004) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2003.10.017 · Cited by 170
Bhol, K. C., & Schechter, P. J. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06575.x · Cited by 161
Shackleford, D. M., Faassen, W. A., Houwing, N. S., Lass, H., Edwards, G. A., Porter, C. J. H., & Charman, W. N. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052522 · Cited by 113
Hydrosols : alternatives for the parenteral application of poorly water soluble drugs
Gassmann, P., List, M., Schweitzer, A., & Sucker, H. (1994) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 103
Bhol, K. C., Alroy, J., & Schechter, P. J. (2004) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01515.x · Cited by 98
Nanocrystals of Poorly Soluble Drugs for Oral Administration
Bushrab, F. N., & Müller, R. H. (2003) · Cited by 43
Self-citationTransmission Electron Microscopy of Mozzarella Cheeses Made from Microfluidized Milk
Tunick, M. H., Hekken, D. L. V., Cooke, P. H., & Malin, E. L. (2001) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf010633c · Cited by 36
DissoCubes—A Novel Formulation for Poorly Soluble and Poorly Bioavailable Drugs
M√oller, R. H., Jacobs, C., & Kayser, O. (2002) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203910337.ch12 · Cited by 26
Nanocrystalline silver inhibits antibiotic-, antiseptic-resistant bacteria
Lyczak, J. B., & Schechter, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.119 · Cited by 10
Cited by
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Nanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,061
Metadata
- Authors
- Müller, R., & Junghanns
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2008-10
- Volume
- 3
- Issue
- 3
- Pages
- 295
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1576568858
- Cited by
- 953
- References
- 21
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.